2024
Laryngeal rare benign non-epithelial tumors and sarcomas emphasizing on chondrosarcomas: A literature review and a case presentation
Vageli D, Doukas P, Paraskeva A, ZACHAROULI K, Judson B, IOANNOU M. Laryngeal rare benign non-epithelial tumors and sarcomas emphasizing on chondrosarcomas: A literature review and a case presentation. Pathology - Research And Practice 2024, 261: 155512. PMID: 39116572, DOI: 10.1016/j.prp.2024.155512.Peer-Reviewed Original ResearchRare tumorNon-epithelialLaryngeal chondrosarcomaMalignant tumorsMesenchymal originBenign non-epithelial tumorsNon-epithelial benign tumorsRare laryngeal tumorNon-epithelial tumorsHigh-grade tumorsLow-grade neoplasmsMesenchymal malignant tumorCases of LCMesenchymal entityRare malignancyEpithelial tumorsMesenchymal tumorsBenign tumorsS100 markersLaryngeal tumorsPrognostic markerLaryngeal malignanciesLaryngeal sarcomasPathological entitySarcoma Study
2023
Rare cases of colonic schwannomas
Gazivoda V, Wang D, Siddique M, Zeng J, Robert M, Pantel H, Mongiu A. Rare cases of colonic schwannomas. Journal Of Surgical Case Reports 2023, 2023: rjac438. PMID: 38163055, PMCID: PMC10757069, DOI: 10.1093/jscr/rjac438.Peer-Reviewed Original ResearchSpindle cell neoplasmTransverse colonMesenchymal tumorsCell neoplasmsProximal transverse colonSegmental transverse colectomyRare spindle cell tumorSpindle cell tumorsColonic schwannomaJumbo forcepsTransverse colectomyPrimary anastomosisSurveillance colonoscopyMucosal biopsiesSubmucosal lesionsColon massElderly malesSubmucosal resectionCell tumorsDeep biopsyElderly femalesSurgical decisionNinth caseRare caseCT scanKlotho Overexpression Is Frequently Associated With Upstream Rearrangements in Fusion-Negative Phosphaturic Mesenchymal Tumors of Bone and Sinonasal Tract
Lee J, Hsieh T, Kao Y, Tsai C, Huang H, Shih C, Song H, Oda Y, Chih-Hsueh Chen P, Pan C, Sittampalam K, Petersson F, Konishi E, Chiu W, Chen C, Carpenter T, Lu T, Chang C, Huang S, Folpe A. Klotho Overexpression Is Frequently Associated With Upstream Rearrangements in Fusion-Negative Phosphaturic Mesenchymal Tumors of Bone and Sinonasal Tract. Modern Pathology 2023, 36: 100336. PMID: 37742927, DOI: 10.1016/j.modpat.2023.100336.Peer-Reviewed Original ResearchConceptsPhosphaturic mesenchymal tumorMesenchymal tumorsSinonasal tractFibroblast growth factor 23Growth factor 23Fusion-positive casesBreak-apart fluorescenceSinonasal locationFISH-positive casesFinal cohortFactor 23Situ hybridizationUncommon neoplasmLarge cohortKlotho overexpressionFGFR1 inhibitionTumorsKL expressionCohortSoft tissueWhole genomic sequencingPromoter methylationConcordant resultsPatientsFurther investigationTransforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib
Roberts C, Rojas-Alexandre M, Hanna R, Lin Z, Ratner E. Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib. Cancers 2023, 15: 3919. PMID: 37568736, PMCID: PMC10417836, DOI: 10.3390/cancers15153919.Peer-Reviewed Original ResearchEpithelial ovarian cancerRepair gene expressionPARP inhibitorsHomologous recombinationGene expressionDNA repair gene expressionCancer cellsLethal gynecologic malignancyDrug-resistant recurrenceDownregulation of genesOvarian cancer cellsGrowth factor betaWild-type cancer cellsDose-dependent mannerDNA repair genesGynecologic malignanciesMesenchymal tumorsOvarian tumorsEpithelial cell lineOvarian cancerMetastatic spreadClinical utilityEOC cellsFunctions of EMTFactor betaUpdate of pediatric bone tumors—other mesenchymal tumors of bone, hematopoietic neoplasms of bone, and WHO classification of undifferentiated small round cell sarcomas of bone
Wang A, Maloney E, Al-Dasuqi K, Irshaid L, Ahmed A, Haims A, Porrino J. Update of pediatric bone tumors—other mesenchymal tumors of bone, hematopoietic neoplasms of bone, and WHO classification of undifferentiated small round cell sarcomas of bone. Skeletal Radiology 2023, 52: 1443-1463. PMID: 36656343, DOI: 10.1007/s00256-023-04286-8.Peer-Reviewed Original ResearchConceptsUndifferentiated small round cell sarcomaSmall round cell sarcomasBone tumorsRound cell sarcomasPediatric populationCell sarcomaMesenchymal tumorsHematopoietic neoplasmsWorld Health Organization classificationGiant cell-rich tumorsPediatric bone tumorsOsteogenic tumorsOrganization classificationVascular tumorsNotochordal tumorsTumorsGenetic sequencing techniquesChondrogenic tumorsCertain lesionsSoft tissueBoneSarcomaNeoplasmsSeparate manuscriptDetailed update
2022
Primary Mesenchymal Tumors of the Thyroid Gland: A Modern Retrospective Cohort Including the First Case of TFE3-Translocated Malignant Perivascular Epithelioid Cell Tumor (PEComa)
Zhang L, Lubin D, Sinard JH, Dickson BC, Antonescu CR, Wu H, Panni RZ, Dogan S, Untch BR, Ghossein RA, Xu B. Primary Mesenchymal Tumors of the Thyroid Gland: A Modern Retrospective Cohort Including the First Case of TFE3-Translocated Malignant Perivascular Epithelioid Cell Tumor (PEComa). Head And Neck Pathology 2022, 16: 716-727. PMID: 35218514, PMCID: PMC9424363, DOI: 10.1007/s12105-022-01428-7.Peer-Reviewed Original ResearchConceptsMalignant perivascular epithelioid cell tumorPerivascular epithelioid cell tumorEpithelioid cell tumorPrimary mesenchymal tumorsMesenchymal tumorsThyroid glandCell tumorsPeripheral nerve sheath tumorsNerve sheath tumorsSmall case seriesBiphasic synovial sarcomaOnly case reportsSolitary fibrous tumorAnaplastic thyroid carcinomaMulti-centric cohortFirst caseRetrospective cohortEpithelioid hemangioendotheliomaSheath tumorsTertiary centerCase seriesClinicopathologic featuresFemale patientsSynovial sarcomaCase reportAssociation of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Orringer D, Placantonakis D, Possemato R, Snuderl M. Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. Neuro-Oncology Advances 2022, 4: vdac163. PMID: 36382106, PMCID: PMC9653172, DOI: 10.1093/noajnl/vdac163.Peer-Reviewed Original ResearchIDH-wt GBMAssociated with poor OSMethylation subclassesOverall survivalPoor OSIDH-wtMolecular subclassesRTK IAssociated with worse survivalAssociated with OSIDH-wildtype glioblastomaPotential survival benefitAssociation of hyperglycemiaAverage glucose valuesAverage glucoseStupp protocolDexamethasone doseMGMT statusSurvival benefitWorse survivalMesenchymal tumorsPerformance statusLow glucose levelsMGMT methylationMolecular subtypes
2021
NCOG-11. ASSOCIATION OF HYPERGLYCEMIA AND TUMOR SUBCLASS ON SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Placantonakis D, Possemato R, Snuderl M. NCOG-11. ASSOCIATION OF HYPERGLYCEMIA AND TUMOR SUBCLASS ON SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology 2021, 23: vi154-vi154. PMCID: PMC8598635, DOI: 10.1093/neuonc/noab196.602.Peer-Reviewed Original ResearchIDH-wt glioblastomaAssociated with poor OSMethylation subclassesDexamethasone doseOverall survivalPoor OSIDH-wtMolecular subclassesAssociated with worse survivalRNA expressionIDH-wildtype glioblastomaPotential survival benefitDNA methylation clustersIsocitrate dehydrogenase (IDH)-wildtypeAssociated with survivalClinical next-generation sequencingPlasma glucose measurementsDNA methylation studiesAverage glucoseNext-generation sequencingStupp protocolMGMT statusMesenchymal tumorsPrognostic significanceSurvival benefitThe 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?
Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, Hornick JL, Inagaki H, Jain D, Lazar AJ, Marino M, Marom EM, Moreira AL, Nicholson AG, Noguchi M, Nonaka D, Papotti MG, Porubsky S, Sholl LM, Tateyama H, Thomas de Montpréville V, Travis WD, Rajan A, Roden AC, Ströbel P. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors? Journal Of Thoracic Oncology 2021, 17: 200-213. PMID: 34695605, DOI: 10.1016/j.jtho.2021.10.010.Peer-Reviewed Original ResearchConceptsThymic epithelial tumorsGerm cell tumorsCell tumorsMesenchymal neoplasmsWHO classificationEpithelial tumorsMediastinal germ cell tumorsLow tumor mutational burdenTumor mutational burdenNew tumor entityClear cell carcinomaPositron emission tomographyClassification of tumorsThymic EpithelialThymic carcinomaFifth editionB3 thymomaTargetable mutationsCell carcinomaMesenchymal tumorsMetaplastic thymomaImmunohistochemical characterizationClinical informationMutational burdenDiagnostic advancesResectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity
Woodard GA, Fels Elliott DR, Yap A, Haro GJ, Kratz JR, Mann MJ, Jones KD, Jablons DM. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity. Annals Of Surgical Oncology 2021, 28: 4953-4959. PMID: 33728541, DOI: 10.1245/s10434-021-09757-7.Peer-Reviewed Original ResearchConceptsSingle-institution reviewInstitution reviewFibrous tumorThoracic cavityLong-term survival dataGiant solitary fibrous tumorBackgroundSolitary fibrous tumorsKaplan-Meier analysisPredictors of recurrenceRare mesenchymal tumorLong-term outcomesRisk of recurrenceMajority of tumorsSolitary fibrous tumorLong-term survivalSFT recurrencePathologic characteristicsRisk stratificationTumor sizeMesenchymal tumorsRisk factorsTumor necrosisVisceral pleuraClinical informationRecurrence
2020
Burosumab for the Treatment of Tumor‐Induced Osteomalacia
de Beur S, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Burosumab for the Treatment of Tumor‐Induced Osteomalacia. Journal Of Bone And Mineral Research 2020, 36: 627-635. PMID: 33338281, PMCID: PMC8247961, DOI: 10.1002/jbmr.4233.Peer-Reviewed Original ResearchConceptsTumor-induced osteomalaciaCutaneous skeletal hypophosphatemia syndromeSerious adverse eventsAdverse eventsWeek 144Week 48Serum phosphorusTreatment-related adverse eventsFibroblast growth factor 23Surface/bone surfaceAcceptable safety profileOsteoid surface/bone surfacePhase 2 studyGrowth factor 23Phosphaturic mesenchymal tumorTransiliac bone biopsiesHuman monoclonal antibodyMineralization lag timePhosphate metabolismQuality of lifeDose titrationFactor 23Safety profileMesenchymal tumorsSkeletal healthA smooth muscle‐derived, Braf‐driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell‐of‐origin
Kondo J, Huh WJ, Franklin JL, Heinrich MC, Rubin BP, Coffey RJ. A smooth muscle‐derived, Braf‐driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell‐of‐origin. The Journal Of Pathology 2020, 252: 441-450. PMID: 32944951, PMCID: PMC7802691, DOI: 10.1002/path.5552.Peer-Reviewed Original ResearchConceptsGastrointestinal stromal tumorsSmooth muscle cellsICC hyperplasiaMuscle cellsTyrosine kinase inhibitor imatinibFrequent driver eventsCommon mesenchymal tumorsSmooth muscle cell progenitorsDevelopment of GISTsKinase inhibitor imatinibLoss of Trp53ICC-DMPGut motilityStromal tumorsMesenchymal tumorsMouse modelInhibitor imatinibInterstitial cellsMutant BRAFBRAF expressionTumorsBRAFHyperplasiaCell progenitorsDriver eventsEndoscopic ultrasound‐guided fine needle aspiration cytology diagnosis of upper gastrointestinal tract mesenchymal tumors: Impact of rapid onsite evaluation and correlation with histopathologic follow‐up
Gilani SM, Muniraj T, Aslanian HR, Cai G. Endoscopic ultrasound‐guided fine needle aspiration cytology diagnosis of upper gastrointestinal tract mesenchymal tumors: Impact of rapid onsite evaluation and correlation with histopathologic follow‐up. Diagnostic Cytopathology 2020, 49: 203-210. PMID: 33006819, DOI: 10.1002/dc.24631.Peer-Reviewed Original ResearchConceptsRapid onsite evaluationSubsequent surgical resectionUpper gastrointestinal tractMesenchymal tumorsSurgical resectionCell blocksEUS-FNAFine needle aspiration cytology diagnosisUltrasound-guided fine-needle aspiration cytologyEndoscopic ultrasound-guided fine-needle aspiration cytologyFine needle aspiration cytologyOnsite evaluationAdditional ancillary testingNeedle aspiration cytologyDiagnostic challengeCytologic casesDiagnostic yieldAncillary testingAspiration cytologyCytologic diagnosisGastrointestinal tractMorphologic overlapCytology diagnosisElectronic databasesLesional materialTargeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia
Hartley IR, Miller CB, Papadakis GZ, Bergwitz C, Del Rivero J, Blau JE, Florenzano P, Berglund JA, Tassone J, Roszko KL, Moran S, Gafni RI, Isaacs R, Collins MT. Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia. New England Journal Of Medicine 2020, 383: 1387-1389. PMID: 32905668, PMCID: PMC7561341, DOI: 10.1056/nejmc2020399.Peer-Reviewed Original ResearchMeSH KeywordsAgedChondrosarcoma, MesenchymalDisease ProgressionFatal OutcomeFibroblast Growth Factor-23Fibroblast Growth FactorsHumansMaleMolecular Targeted TherapyNeoplasms, Connective TissueOsteomalaciaParaneoplastic SyndromesPhenylurea CompoundsPositron Emission Tomography Computed TomographyPyrimidinesReceptor Protein-Tyrosine KinasesReceptor, Fibroblast Growth Factor, Type 1Molecular and clinicopathologic characterization of intravenous leiomyomatosis
Ordulu Z, Chai H, Peng G, McDonald AG, De Nictolis M, Garcia-Fernandez E, Hardisson D, Prat J, Li P, Hui P, Oliva E, Buza N. Molecular and clinicopathologic characterization of intravenous leiomyomatosis. Modern Pathology 2020, 33: 1844-1860. PMID: 32341498, PMCID: PMC7483566, DOI: 10.1038/s41379-020-0546-8.Peer-Reviewed Original ResearchConceptsIntravenous leiomyomatosisAggressive clinical behaviorClinical behaviorArray comparative genomic hybridizationCyclin D1Uterine smooth muscle tumorsSmooth muscle tumorsSmooth muscle proliferationRecurrent chromosome alterationsCommon genetic alterationsFH immunohistochemistryClinicopathologic characterizationImmunohistochemical findingsMesenchymal tumorsMuscle tumorsBenign appearanceMuscle proliferationUterine leiomyomaGroup 1Group 3Nonneoplastic tissuesIndex scoreVascular morphologyProtein expressionComparative genomic hybridization
2019
A Case Study Evaluating the Diagnosis and Treatment of a Rare Mesenchymal Tumor
Shinder B, Sack J, Sadimin E, Tunuguntla H. A Case Study Evaluating the Diagnosis and Treatment of a Rare Mesenchymal Tumor. Urology 2019, 131: e1-e2. PMID: 31247212, DOI: 10.1016/j.urology.2019.06.019.Peer-Reviewed Case Reports and Technical NotesConceptsCellular angiofibromaPainless right inguinal massRare mesenchymal tumorRight inguinal massBenign mesenchymal neoplasmLimited treatment optionsOval-shaped massSurgical excisionInguinal massMesenchymal tumorsMesenchymal neoplasmsCT scanTreatment optionsSpermatic cordImmunohistochemical analysisRadiographic featuresImaging modalitiesAngiofibromaDiagnostic casesCD34NeoplasmsTumorExcisionDesminCordPhosphaturic mesenchymal tumor of the nasal cavity: Clinicopathologic correlation is essential for diagnosis
Kerr A, Rimmer R, Rosen M, Evans J, Tuluc M, Mardekian S. Phosphaturic mesenchymal tumor of the nasal cavity: Clinicopathologic correlation is essential for diagnosis. Human Pathology Reports 2019, 15: 33-36. DOI: 10.1016/j.ehpc.2018.10.013.Peer-Reviewed Original ResearchPhosphaturic mesenchymal tumorMesenchymal tumorsFibroblast growth factor 23Growth factor 23Nasal cavity massDistinct clinical presentationsLaboratory abnormalitiesOncogenic osteomalaciaClinical presentationFactor 23Patient's symptomsPathologic findingsCavity massHistopathologic examinationRare neoplasmClinicopathologic correlationNasal cavityFGF23 mRNATumorsTumor cellsSymptomsDiagnosisSitu hybridizationResectionOsteomalacia
2018
Phosphaturic mesenchymal tumors: what an endocrinologist should know
Boland J, Tebben P, Folpe A. Phosphaturic mesenchymal tumors: what an endocrinologist should know. Journal Of Endocrinological Investigation 2018, 41: 1173-1184. PMID: 29446010, DOI: 10.1007/s40618-018-0849-5.Peer-Reviewed Original ResearchConceptsTumor-induced osteomalaciaPhosphaturic mesenchymal tumorMesenchymal tumorsCase of tumor-induced osteomalaciaRare cause of osteomalaciaPhosphaturic hormone fibroblast growth factor 23Recurrent genetic eventsHormone fibroblast growth factor 23Renal phosphate wastingFibroblast growth factor 23Autocrine/paracrine signaling loopTubular phosphate reabsorptionProgressive muscle weaknessProximal tubular phosphate reabsorptionConstellation of symptomsMolecular genetic aspectsBone painCalcitriol therapyCurative surgeryOncogenic osteomalaciaOffending tumorRare causeSurgical removalClinical featuresPrimary treatment
2016
Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?
Giuliano K, Nagarajan N, Canner J, Najafian A, Wolfgang C, Schneider E, Meyer C, Lennon AM, Johnston FM, Ahuja N. Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ? Journal Of Surgical Oncology 2016, 115: 351-357. PMID: 27885685, DOI: 10.1002/jso.24514.Peer-Reviewed Original ResearchConceptsSmall intestine gastrointestinal stromal tumorGastrointestinal stromal tumorsCause-specific mortalityGIST patientsDiagnosis of GISTCases of GISTLarge nation-wide studyGastric gastrointestinal stromal tumorsGastric GIST patientsCommon mesenchymal tumorsFive-year survivalApproval of imatinibNation-wide studySEER databaseStromal tumorsMesenchymal tumorsGastrointestinal tractAge 50PatientsSurvival analysisSimilar outcomesTumorsPrevious reportsFrequent useOutcomesThe BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2016, 34: 3638-3647. PMID: 27480147, PMCID: PMC5065110, DOI: 10.1200/jco.2015.66.0084.Peer-Reviewed Original ResearchDisease control rateKRAS wild-type patientsMedian overall survivalProgression-free survivalWild-type patientsArm 1Overall survivalKRAS statusArm 3Lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerBiomarker-driven treatment strategiesLung Cancer Elimination (BATTLE) trialMedian progression-free survivalImproved progression-free survivalBiomarker-Integrated ApproachesReal-time biopsyPrimary end pointCell lung cancerPrior therapyUmbrella studyAdvanced NSCLCControl rateMesenchymal tumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply